Soligenix Inc  

(Public, OTCBB:SNGX)   Watch this stock  
Find more results for OTC:SNGX
1.34
-0.09 (-6.29%)
Sep 1 - Close
OTCBB data delayed by 15 mins - Disclaimer
Currency in USD
Range 1.34 - 1.43
52 week 0.91 - 2.95
Open 1.39
Vol / Avg. 87,363.00/163,711.00
Mkt cap 35.35M
P/E     -
Div/yield     -
EPS -0.47
Shares 26.38M
Beta 2.23
Inst. own 17%
Nov 9, 2015
Q3 2015 Soligenix Inc Earnings Release (Estimated) Add to calendar
Aug 12, 2015
Q2 2015 Soligenix Inc Earnings Release
  

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -361.66% -95.23%
Operating margin -185.01% -152.79%
EBITD margin - -149.30%
Return on average assets -283.16% -88.14%
Return on average equity - -
Employees 17 -
CDP Score - -

Address

29 Emmons Dr Ste C10
PRINCETON, NJ 08540-5919
United States - Map
+1-609-5388200 (Phone)
+1-609-4526467 (Fax)

Website links

Description

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company develops product candidates in the areas of inflammation, oncology and biodefense. It operates in two segments: BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment is developing a first-in-class photo-dynamic therapy (SGX301) utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, formulations of oral beclomethasone 17,21-dipropionate for the prevention or treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201), and its innate defense regulator (IDR) technology (SGX942) for the treatment of oral mucositis. The Vaccines/BioDefense segment includes development programs for RiVax, its ricin toxin vaccine candidate, VeloThrax, an anthrax vaccine candidate, OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate and SGX943, a melioidosis therapeutic candidate.

Officers and directors

Christopher J. Schaber Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 48
Joseph M. Warusz CPA Acting Chief Financial Officer, Vice President - Finance, Corporate Secretary
Age: 58
Oreola Donini Ph.D. Senior Vice President, Chief Scientific Officer
Age: 43
Richard C Straube M.D. Senior Vice President and Chief Medical Officer
Age: 63
Marco Maria Brughera Director
Age: 59
Keith L. Brownlie CPA Independent Director
Age: 62
Gregg A. Lapointe C.P.A. Independent Director
Age: 56
Robert Joseph Rubin Independent Director
Age: 69
Jerome B. Zeldis M.D., Ph.D. Independent Director
Age: 64